Background and Aims: Thiopurines are widely used in the management of inflammatory bowel diseases. However, their minimum effective dose and dose-response relationship remain undefined, and evidence about their use in clinical practice is mostly heterogeneous. This systematic review and meta-analysis aimed: i] to assess the clinical value of 6-thioguanine nucleotide thresholds; and ii] to compare mean 6-thioguanine nucleotide concentrations between patients in clinical remission vs. those with active disease. Methods: A systematic literature search was carried out using four databases. Statistical heterogeneity was assessed with the I 2 statistic followed by subgroup and sensitivity analyses. Odds ratios were computed using the random-effects model. Results: A total of 1384 records were identified in the systematic search, of which 25 were retained for further analysis: 22 were used in the cut-off comparisons and 12 were used in the 6-thioguanine nucleotide mean differences analysis. The global odds ratio for remission in patients with 6-thioguanine nucleotide levels above the predefined thresholds was 3. Conclusions: This study reinforces the link between 6-thioguanine nucleotide levels and clinical remission in inflammatory bowel diseases, also exploring the validity of specific 6-thioguanine nucleotide thresholds to predict clinical outcomes.
Introduction
Inflammatory bowel diseases [IBD] are complex, multifactorial and known to arise in response to a complex interplay of individual genetics, environmental triggers, and changes in the intestinal microbiome. The combination of those factors may stimulate an unbalanced immune response, which in turn leads to a chronic intestinal inflammation. 1 IBDs have a substantial impact on patients' health-related quality of life [HRQoL] , given their early onset, main symptoms, fluctuating course, and lack of curative options. Moreover, IBD monitoring and treatments carry considerable expense to health care systems. 2 Thiopurines, comprising azathioprine [AZA], mercaptopurine [MP] , and thioguanine [TG] , are part of the therapeutic armamentarium used in IBD treatment. Their pharmacologically active metabolites are 6-thioguanine nucleotides , and their immunosuppressive effect is attributed to their incorporation into nucleic acids and consequent inhibition of lymphocyte proliferation, as well as to their important role in inducing apoptosis. 3 Indeed, these drugs specifically target the Vav1/Rac1 signalling pathway of T lymphocytes: 6-thioguanine triphosphate [one of the downstream metabolites] binds to Rac1 as a competitive antagonist of guanosine triphosphate [GTP] and converts a co-stimulatory signal into an apoptotic one. 4, 5 These drugs are steroid-sparing agents and are indicated after surgery in Crohn's disease [CD] , in case of failure of maintenance therapy with 5-ASA [5-aminosalicylic acid] in ulcerative colitis [UC] , and as concomitant immunosuppressive drugs during therapy with biologic agents. 6 Notwithstanding, the moment of introduction of these immunomodulators in IBD therapy is being progressively anticipated to earlier stages of the disease evolution-in fact, the latest therapeutic approaches favour a top-down strategy as an attempt to alter the natural history of these conditions. 7 Traditionally, thiopurines dosing is weight-based, starting at a low dosage and being then gradually increased until reaching full therapeutic levels [2.0 to 2.5 mg/kg/day of AZA or 1.0 to 1.5 mg/kg/day of MP], following haematological monitoring. 8 However, this conventional dosing strategy has been associated with intolerance, inefficacy, and adverse effects, leading to the cessation of therapy in 9% to 25% of patients. 8, 9 An alternative dosing strategy based on thiopurine S-methyltransferase [TPMT] activity may prevent early leukopenia, but the other causes of intolerance and adverse effects remain apparently constant. 10 According to the literature, therapeutic response to thiopurines is influenced by many factors, including genetic differences, age, and disease duration and severity, as well as comorbidities. An inadequate response to these drugs is, in most cases, related to underdosing and/or poor compliance. 11 On the other hand, drug adverse reactions may be related to drug metabolism or be of an idiosyncratic origin, the latter accounting for 1% to 7% of all cases. 10 As such, surveillance plays a key role for prompt identification of loss of response and toxicity. 11 The latest developments on thiopurines' pharmacokinetics and pharmacodynamics, allied to a growing clinical experience, has allowed the optimisation of dosing regimens with a positive impact on efficacy and safety. 10 Nonetheless, the minimum effective dose is not yet consensual, and the dose-response relationship is still controversial. 9 The usefulness of TPMT phenotyping and genotyping and also of therapeutic drug monitoring [through analysis of 6-TGN levels, blood count measurements, or evaluation of erythrocyte mean corpuscular volume as a surrogate marker of 6-TGN concentration] have recently been addressed. 6, 12, 13 However, due to studies' heterogeneity and conflicting results, its application to clinical practice is still debatable. 14 In fact, according to the current European and American guidelines [ECCO and AGA], the available scientific evidence is insufficient to recommend the routine measurement of 6-TGN metabolites. 15, 16 This paper's aim was to systematically review all published evidence regarding the use of thiopurines in the treatment of IBD. The specific objectives were: i] to determine whether there was a relationship between the 6-TGN thresholds and clinical outcomes; and ii] to analyse the differences of mean 6-TGN concentrations between patients with active disease and those achieving remission. To do so, all results from selected articles were quantitatively integrated in a detailed meta-analysis.
Materials and Methods

Search strategy
This study was conducted following the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [PRISMA] Guidelines, 17 as well as the Cochrane Collaboration Guidelines for reporting meta-analyses. 18 The published studies were retrieved after a literature search including four electronic databases: PubMed . In order to ensure that all pertinent articles were included, the reference lists of the studies selected from the databases were manually reviewed.
Eligibility and inclusion/exclusion criteria
Any study enrolling adult or infant patients previously diagnosed with IBD using clinical, endoscopic, radiological, and/or pathological features, and using a commonly accepted method to assess disease progression, was considered eligible for inclusion in this systematic review. Moreover, the following studies' designs were considered: randomised controlled trials [RCT] , cohort studies, and case series. The inclusion criteria were: i] articles studying the association between 6-TGN concentrations and clinical outcomes [active disease or remission]; and ii] English language. No restriction in terms of publication dates was applied. Whenever full-text articles were unavailable, abstracts were included if considered critically relevant. Exclusion criteria included: i] systematic reviews or guidelines; ii] studies involving patients with diseases other than IBD; or iii] studies involving patients receiving thiopurines in association with biological agents or with a low dose of allopurinol. Indeed, none of the studies where allopurinol had been added to thiopurine treatment was eligible as they all failed the criterion of relating 6-TGN levels to clinical outcomes. Animal studies were also excluded, as recommended in the Cochrane Handbook of Systematic Reviews of Interventions.
Study selection and data collection process
The studies identified using the databases or the reference lists were independently screened by two reviewers. Any study in which title and abstract clearly indicated that it failed to meet the previously described selection criteria, was immediately excluded from further analysis. In all the other studies, the full text was considered in order to determine its inclusion or exclusion.
The following information was collected from the selected studies: journal and authors' names, publication year, article type, study design, cohort's geographical origin, number of patients enrolled, cohort's age group [paediatric vs. adult], IBD type, type of thiopurine used and treatment duration, 6-TGN serum levels, 6-TGN cut-offs, methodology used in 6-TGN quantification, definition of clinical outcomes, and proportion of patients in remission or with active disease above and below the 6-TGN cut-off defined. Patients labelled as 'partial responders' were considered to have active disease.
Quality assessment
A funnel plot was used as a visual aid to detect potential publication bias and/or systematic heterogeneity. The quality of the included studies was further independently assessed by two investigators, following the quality assessment tool [QATSDD] described by Sirriyeh et al. [2012] . 19 This assessment tool includes 16 items scored from 0 to 3, which reflect the intelligibility of description of aims and setting, data quality, methodology, and self-assessment. Two of the items concern only qualitative studies, and therefore were not evaluated in this study. For each paper, the scores were added and divided by the maximum possible score [42] to obtain the paper's overall quality score.
Statistical analysis
The main variable analysed in this meta-analysis was the clinical response, defined as remission vs. active disease. The proportion of patients in remission with concentrations of 6-TGN above and below the defined threshold values was extracted or calculated from each article included. These two groups were then compared using random-effects meta-analysis and following Cochran-MantelHaenszel statistics to estimate the odds ratio [OR] for remission and its 95% confidence interval [95% CI]. This methodology assumes that the effects estimated in the different studies are not identical but are similar, and follow some distribution. 20 All estimates were re-computed from the descriptions provided in the original articles, which might result in values that are slightly different from the original ones. Moreover, random-effects models were used to test whether mean 6-TGN concentrations differ among patients in remission or with active disease.
All p-values are two-sided and have a 5% significance level. Review Manager version 5.3 was used to calculate the ORs and the corresponding 95% CIs, to generate the forest and funnel plots, and to evaluate the mean 6-TGN differences. Statistical heterogeneity was assessed using the I 2 statistic [values above 50% indicate a substantial level of heterogeneity] and by performing subgroup analyses on the following variables: i] paediatric/adult population; ii] single/ multiple 6-TGN measurements; iii] 6-TGN determination methodology; iv] duration of treatment; v] patient's origin; and vi] tools used to evaluate clinical remission. The stability of the combined ORs and the weight of each study in the heterogeneity analysis was assessed by performing a sensitivity analysis omitting one study at a time in a stepwise fashion.
Results
Bibliographic search and study selection
The selection strategy followed is summarised in Figure 1 . The initial electronic database search yielded 1384 results, of which 289 were excluded: 141 for being neither observational studies nor controlled trials; 105 for being duplicates; and 43 for not involving humans. Of the remaining studies [n = 1095], 1034 were excluded after screening their titles and abstracts: 915 did not relate predefined 6-TGN thresholds with clinical outcomes; five were guidelines; six enrolled patients with comorbidities; six where abstract and full text were not available; and 102 were written in a language other than English. A total of 61 papers were then considered for full-text analysis, from which 36 were excluded: 19 did not present 6-TGN mean values nor defined cut-offs; eight assessed an outcome not considered in our meta-analysis [ie different from clinical remission/disease activity]; five did not depict 6-TGN levels; two had 6-TGN levels expressed in units other than those used in our analyses; one where the definition of remission was endoscopic; and one that was unavailable.
Overall, 25 studies matched the inclusion criteria of this systematic review, which included a total of 3515 patients with IBD [2093 in remission and 1422 with active disease] [ Table 1 ]. From the 25 studies included, 22 were used in the comparison of 6-TGN cutoff values [as three 8, 21, 22 did not have all the information needed for this], and 11 were used to compute the pooled 6-TGN levels among patients in remission vs. those with active disease. 36, 37 did not specify the IBD type. However, the impact of IBD type in the results could not be assessed, as only three studies 33, 38, 39 had the results stratified by this criterion. Moreover, selected studies also varied widely regarding disease severity definition. Indeed, four different classification systems were used for patients with CD (Harvey-Bradshaw Activity Index [HBI], Crohn's Disease Activity Index [CDAI], Paediatric Crohn's Disease Activity Index [PCDAI] ,and Inflammatory Bowel Disease Questionnaire [IBDQ]), and for UC this number was even higher. Also, three 29, 30, 35 studies used a clinical remission definition based on the clinicians' global assessment.
Study descriptions
According to the literature, 40 6-TGN concentration in erythrocytes is related to the extent of incorporation of this nucleotide in peripheral blood leukocyte DNA, being a surrogate marker for the assessment of thiopurine therapy. Multiple per-patient measurements of 6-TGN levels were performed in nine studies, 21, [25] [26] [27] [28] 30, 32, 36, 37 whereas in 16 studies only one determination per patient was carried out. These determinations were made by high-performance liquid chromatographic [HPLC] 45 and two followed the procedures described by Erdmann et al. [1990] . 46 Two 29,37 studies failed to mention the determination methodology. In order to compare the data obtained from different methodologies and following a previously recommended strategy, 47 ,48 the Lennard assay was used as 'standard' and the conversion factor of 1.6 was applied to the results obtained 49, 50 using the Erdmann method, whereas a conversion factor of 2.6 was applied to the results obtained using the Dervieux and Boulieu method. These three methodologies determine 6-TGN levels following monophosphate, diphosphate, and triphosphate hydrolysis and are based on HPLC coupled with MS or UV detection. Even though the results vary according to the assay, due to the extent of hydrolysis, it was been demonstrated that there is a high degree of correlation among methodologies. 14, 49 There was considerable variability concerning the definition of 6 of the 22 studies used for 6-TGN cut-offs comparison considered two threshold values. In these cases, the lowest threshold value was used in the pooled results, whereas both cut-offs were considered in the per-'6-TGN level' analysis. The computation and analysis of a forest plot revealed a considerable amount of variability between studies, even though the funnel plot does not suggest the existence of substantial publication bias.
The results of the methodological assessment are presented in the last column of Table 1 ]), yielding an average quality score for all papers of 71.43 ± 9.39%. The studies with lower methodological quality scores were those where IBD severity was defined through global assessment and where the assay used for 6-TGN measurements was not stated. Almost all evaluated studies had the maximum possible score for the parameters: 'explicit theoretical framework', 'statement of aims/objectives', 'clear description of research setting', and 'description of procedure for data collection', whereas the lowest scores were found for criteria: 'evidence of sample size considered in terms of analysis' and 'evidence of user involvement in design'. The studies considered in this analysis had a significant degree of heterogeneity [p < 0.001; I 2 = 79%]. As such, sensitivity analyses were performed. However, the exclusion of each study individually has neither eliminated the heterogeneity nor changed considerably the pooled OR. Subgroup analyses were then performed to further explore this issue. Considering that the number of subgroups must be reduced to avoid spurious statistical findings, the following comparisons were made Studies were stratified into six groups according to their cut-offs, and the OR for remission was separately computed for each of these groups [ Figure 3 Figure 4 depicts the analysis of the mean differences reported for the 6-TGN levels between patients in clinical remission and patients with active disease. This information was extracted from eight 29, 32, 35, 36, 39, 43, 49, 50 articles used for cut-off analysis and from three studies 8, 21, 22 that were solely used in this section. A statistical assessment revealed significant heterogeneity among the 11 considered studies [p < 0.001; I 2 = 92%], which could not be eliminated through an individual exclusion approach [sensitivity analysis]. Overall, the mean 6-TGN levels were higher among patients in remission than in those with active disease, with a pooled difference of 63. 
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Discussion
Thiopurines are widely used as immunosuppressive drugs in the treatment of IBD, and their efficacy has been demonstrated in a broad range of clinical presentations. 52 However, a few questions remain unanswered concerning intolerance, loss of therapeutic action, and adverse effects, and these missing links may preclude further drug administration or may even be life-threatening. 53 An association between 6-TGN and clinical remission was described for the first time by Cuffari et al. [1996] , 23 who reported a significant inverse relationship between disease activity and nucleotide levels. And in fact, further studies have consistently related thiopurines' clinical efficacy with serum 6-TGN levels of 235-450 pmol/8 × 10 8 RBC. 25 Notwithstanding, and despite the theoretical pertinence of monitoring thiopurine metabolites for therapy optimisation, thiopurine measurement is not recommended by the main guidelines for IBD management, and therefore only a small number of IBD gastroenterologists do it as part of their daily practice. 51 Moreover, the existence of a 6-TGN cut-off level clearly and consistently linked with a clinical outcome remains controversial, given the marked inter-and intra-individual variability of 6-TGN levels. As far as the authors know, this is the first meta-analysis that considers different thresholds of 6-TGN that have been reported in the literature [200, 225, 230, 235, 250 and 260 pmol/8 × 10
8 RBC]. This analysis aimed to overcome the lack of evidence for recommending a specific 6-TGN cut-off as a marker of clinical remission. 54 The global analysis concerning the association between 6-TGN levels and patient clinical status unveiled that those patients with 6-TGN levels above the different cut-off levels were 3.95 times more likely [95% CI, 2.63-5.94] to achieve clinical remission. This value is similar to others obtained previously: a meta-analysis published in 2006, 48 including six studies and 437 patients, described an OR for remission of 3.27 [95% CI, 1.71-6.27], and a more recent study from 2014, 14 Even so, it must be noted that 36.96 ± 17.95% of the patients who achieved remission in our study cohort did not have 6-TGN values above the considered thresholds, suggesting that other factors besides these metabolite levels play a role in the response to MP and AZA. Indeed, and even though 6-TGN monitoring provides an insight on thiopurine metabolism, factors like age, gender, disease duration and severity, comorbidities, and concomitant medication have been reported to play a role in these drugs' efficacy. 55 In addition, preliminary reports suggest that there are other parameters that may be more reliable in the prediction of therapeutic efficacy, like the 6-MMPR:6-TGN ratio. 56 More recently, emphasis has been laid on the relevance of monitoring the pharmacodynamics of thiopurines directly in leukocytes through the determination of Rac1-GTP and other downstream molecular mediators. 57 The analysis of the difference between means has shown that 6-TGN levels of patients in clinical remission are significantly higher than those observed in patients with active disease, with a mean pooled difference of 63. 37 the authors in their studies, and made no estimation for those that reported only the median or range, in order to avoid possible interferences. Interestingly, two of the studies 29, 49 found that the 6-TGN levels were actually higher in patients with active disease when compared with those in clinical remission. Even though those results did not differ statistically [95% CI includes zero], this inverted pattern may be due to the use of cohorts with particularly severe disease conditions-in which a higher serum concentration would be the result of a higher dosage motivated by the severity of the symptoms, or in which the time spent from the beginning of the medication to the study assessment was not long enough to allow the positive effects of medication to take place.
The studies used to compute ORs for clinical remission and 6-TGN mean values were significantly heterogeneous, and this heterogeneity could not be eliminated through sensitivity analysis. A subgroup analysis was carried out to further explore this issue, and no observable subgroup effect was found regarding the variables: paediatric/adult population; methodology used for dosing the 6-TGN; or the use of single/multiple 6-TGN measurements. This last point is particularly important, as according to a prospective cohort study, 58 patients on a stable AZA dose may present variable levels of 6-TGN over time, bringing into question the value of a single measurement. Interestingly, and opposite to our results, a previous meta-analysis on the same topic reported that heterogeneity between studies could be assigned to differences in the analytical methodologies used for 6-TGN measurements. This discrepancy with our results may be due to differences in the studies included. Indeed, and when compared twiththe report published in 2014, 14 there are 10 additional studies included in ours, using five different procedures for the quantification of nucleotide levels [four using HPLC and one with LC-MS], whereas in the former only three methodologies were compared.
The therapeutic effects of thiopurines are reported to take place between 12 to 17 weeks after their initiation. 10 The delayed onset of action may be due to the existence of a certain latency between treatment initiation and thiopurine-induced apoptosis, as well as to the fact that T cells whose cycle is already arrested are still able to have effector cell function, further enhancing a pro-inflammatory environment. 5, 59 Even so, no significant subgroup effect regarding the minimal time [below or above 3 months] between treatment initiation and 6-TGN determination was unveiled in the present study. Moreover, and even though the activity of the enzymes involved in thiopurine metabolism is known to vary among ethnic groups, 60 no significant heterogeneity was found between studies enrolling patients from different continents [America, Asia, or Europe]. This is in agreement with what has been previously reported by other authors. 14, 60 On the other hand, heterogeneity between studies may be associated with differences in the tools used for disease severity definition in the case of UC, for which the diversity of classification systems used was higher than for CD. Indeed, upon splitting data into subgroups according to the classification criteria, a quantitative interaction-with constant direction but a variable size of the effect-was observed. This finding corroborates the pertinence of developing a validated and pragmatic severity classification to guide current therapeutic strategies for IBD, as recently highlighted by Peyrin-Biroulet et al. [2016] . 61 This study has a few methodological limitations that should be taken into consideration. First, it is important to consider that clinicians may be more prone to order 6-TGN testing in patients whom disease remains active despite the pharmacological treatment. Accordingly, the proportion of non-responders in this meta-analysis [74% of the 3292 patients] is clearly higher than that observed in clinical practice and in clinical trials. 62 Second, and due to the limited availability of data from the included studies, the results of patients with CD and UC were pooled together. The analysis of the impact of the type of disease could have been important-in fact, Fangbin et al. [2016] 33 reported that 6-TGN levels correlated well with clinical responsiveness in CD patients but not in UC patients. Third, some parameters whose assessment was out of the scope of this review may have had an unpredictable effect on clinical outcomes. Among these, one should highlight different treatment regimens and durations, disease-related factors, and genetic polymorphisms. Fourth, the variability in design and methodology of the included studies and the lack of randomisation and blinding may have influenced study outcomes and conclusions. Also, most of the included studies were prospective, and the existence of bias related to losses to follow-up cannot be disregarded. Finally, the clinical outcome definition was heterogeneous among studies. As to avoiding the variability inherent in clinical assessment scales, the use of endoscopic and/or objective biomarkers would have been preferable and should be considered in future studies. Also, the utility of measuring 6-TGN concentrations in the setting of combination with biological agent therapy remains poorly understood. 
